Coronavirus (COVID-19) Q&A

Noninvasive ventilation (NIV) may help COVID-19 patients in respiratory failure avoid invasive mechanical ventilation but may also lead to delays in intubation with potential for worse clinical outcomes.

Domenico L. Grieco, MD, of Fondazione Policlinico Agostino Gemelli IRCCS in Rome, Jesse B. Hall, MD, of the University of Chicago, and Laveena Munshi, MD, MSc, of Sinai Health System/University Health Network of the University of Toronto join JAMA's live Q&A series to discuss helmet NIV, high-flow nasal oxygen, and other NIV modalities in the management of hypoxic coronavirus patients. Recorded March 25, 2021.

Related Content:

Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure

Respiratory Support During the COVID-19 Pandemic: Is It Time to Consider Using a Helmet?

Noninvasive Ventilation of COVID-19 Patients

The Price of Success—How to Evaluate COVID-19 Vaccines When They’re Available Outside of Clinical Trials; When the Human Voice Speaks Volumes About Lung Function; COVID-19 Vaccines vs Variants—Determining How Much Immunity Is Enough

Related Articles:

The Price of Success—How to Evaluate COVID-19 Vaccines When They’re Available Outside of Clinical Trials

When the Human Voice Speaks Volumes About Lung Function

COVID-19 Vaccines vs Variants—Determining How Much Immunity Is Enough

Coronavirus trends, variants, vaccines, treatment, and more. JAMA Associate Editor Preeti Malani, MD, MSJ, also from the University of Michigan, and Emory University School of Medicine's Carlos del Rio, MD, return to JAMA's Q&A series to discuss the latest in COVID-19 medicine and public health. Recorded March 15, 2021.

Related Content:

• COVID-19 in 2021—Continuing Uncertainty
• Coronavirus Update With Carlos del Rio and Preeti Malani
• Frequently Asked COVID Vaccine Questions

Genetic variants of the SARS-CoV-2 virus are emerging but so far do not seem to have caused breakthrough infections in people with previous infection or in those who have been vaccinated. John P. Moore, PhD, of Weill Medical College of Cornell University in New York, joins JAMA's Q&A series for an update on the latest variants and what you need to know. Recorded March 4, 2021.

Related Article:

Approaches for Optimal Use of Different COVID-19 Vaccines

Interview with Christopher J.L. Murray, MD, DPhil, author of The Potential Future of the COVID-19 Pandemic: Will SARS-CoV-2 Become a Recurrent Seasonal Infection?

Related Article(s):

The Potential Future of the COVID-19 Pandemic

Interview with James C. Robinson, PhD, author of Funding of Pharmaceutical Innovation During and After the COVID-19 Pandemic

Nancy E. Messonnier, MD is director of the National Center for Immunization and Respiratory Diseases (NCIRD) at the Centers for Disease Control and Prevention (CDC) and leads the CDC’s efforts on COVID-19 vaccination. She joins JAMA's Q&A series to discuss the agency's response to emerging coronavirus variants, the FDA advisory hearings on the new Johnson & Johnson vaccine, and other agency activities and priorities related to COVID-19 control. Recorded February 26, 2021.

Related Content:

• Genetic Variants of SARS-CoV-2—What Do They Mean?
• Coronavirus Vaccine Update From the CDC With Nancy E. Messonnier, MD
• SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants
• Experts Discuss COVID-19—Vaccine Doses, Virus Variants, and More
• Emergence of a Novel SARS-CoV-2 Variant in Southern California
• SARS-CoV-2 Variants of Concern in the United States
• Pregnant People Getting Mixed Messages About COVID-19 Vaccines
• The Johnson & Johnson Vaccine for COVID-19
• SARS-CoV-2 Viral Variants—Tackling a Moving Target
• Vaccine Distribution—Equity Left Behind?
• Taking Vaccine to Where the Virus Is—Equity and Effectiveness in Coronavirus Vaccinations?

The Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines are the first of many being tested for widespread use. Buddy Creech, MD, MPH, director of the Vanderbilt Vaccine Research Program, reviews these and other vaccines likely to become available, including products that use inactivated, protein subunit, and viral vector immunization strategies.

Related Article(s):

SARS-CoV-2 Vaccines

The CDC coordinated a massive effort to immunize nearly all nursing home and long-term care facility residents in the US against COVID-19 infection in the month after vaccine approval. Ruth Link-Gelles, PhD, MPH, CDC staff epidemiologist and Lieutenant Commander of the US Public Health Service Commissioned Corps, describes how.

Related Article(s):

• First-Dose COVID-19 Vaccination Coverage Among Skilled Nursing Facility Residents and Staff
• Nursing Homes’ Next Test—Vaccinating Workers Against COVID-19

Researchers Investigate What COVID-19 Does to the Heart; “Important Conversations” Are Needed to Explain the Nocebo Effect; Therapists Donate Their Time to Counsel Distressed Health Care Workers

Related Article:

Researchers Investigate What COVID-19 Does to the Heart

“Important Conversations” Are Needed to Explain the Nocebo Effect

Therapists Donate Their Time to Counsel Distressed Health Care Workers